GET DAILY SIGNALSPurple Biotech (PPBT) Rises +34% Over 30 Days on Pipeline Catalyst
Key Takeaways
- Purple Biotech (PPBT) gained roughly 34% over the trailing 30 days, with the latest close at $1.63 compared with $1.22 about a month earlier.
- The rally accelerated in November after the company announced its lead candidate IM1240 was selected for an oral presentation at the EORTC-NCI-AACR Symposium.
- The advance marks a sharp rebound from a late-October low near $0.94, underscoring elevated volatility in this small-cap, clinical-stage biotech.
- Over the last quarter, PPBT has whipsawed between a September surge and a mid-October pullback, ultimately posting a modest gain.
- As a pre-revenue developer, Purple Biotech's share price is driven primarily by pipeline milestones and sentiment rather than current fundamentals.
- For additional data, explore detailed Price Targets, Earnings, and Forecast pages.
- Discover Trending AI Robots to see how algorithmic strategies are approaching the current market.
Purple Biotech (PPBT) Company Overview and Market Position
Purple Biotech Ltd. is a clinical-stage oncology company headquartered in Rehovot, Israel, and listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker PPBT. The company develops next-generation immunotherapies designed to maximize anti-cancer potency while limiting toxicity. Its lead program, CAPTN-3, is a platform of capped (masked) tri-specific antibodies that simultaneously engage T cells and NK cells against tumor targets, with the goal of confining immune activation to the tumor microenvironment.
The platform's lead candidate, IM1240, is advancing toward clinical entry, while a second candidate, IM1305, remains in preclinical development. Purple Biotech's broader pipeline also includes CM24, a CEACAM1-blocking antibody evaluated in a Phase 2 pancreatic cancer study, and NT219, a dual IRS1/2 and STAT3 inhibitor, though further development of those assets depends on partnering or additional financing. As a pre-revenue company, Purple Biotech competes in the crowded immuno-oncology space and is closely followed by investors focused on early-stage drug-development catalysts.
Purple Biotech (PPBT) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, PPBT climbed approximately 33.6%, from a close of $1.22 on October 14, 2026, to $1.63 on November 13, 2026. The move was not linear: the stock slid to a late-October trough near $0.94 before reversing sharply in early November and accelerating into the low-to-mid $1.60s. I also checked this using Tickeron’s AI Trend Prediction Engine to see how the patterns compared with similar names.
The last quarter has been considerably more volatile. From a close of $1.51 on August 13, 2026, to $1.63 on November 13, the shares gained roughly 8%. Within that window, PPBT spiked in early September following a U.S. patent allowance, pulled back through September and October, and then recovered into November. This pattern reflects the high-beta, catalyst-driven trading typical of small-cap clinical-stage biotech names.
What Drove PPBT Stock Price in the Last 30 Days
The most significant verified catalyst in the trailing 30-day window was Purple Biotech's October 29, 2026, announcement that its IM1240 abstract had been selected for an oral presentation at the 38th EORTC-NCI-AACR Symposium. The selection focused investor attention on the CAPTN-3 platform and the lead candidate's preclinical anti-tumor activity and safety profile ahead of the scheduled November 20, 2026 presentation.
The stock's November advance also reflected a technical rebound from an oversold late-October low. Thin trading liquidity and a relatively small float amplified the move in both directions. Because Purple Biotech generates no meaningful revenue, price action was driven almost entirely by pipeline news flow and sentiment rather than earnings or balance-sheet developments.
What Drove PPBT Stock Performance Over the Last Quarter
The broader three-month trend was shaped by a series of company-specific milestones. In early September 2026, the U.S. Patent and Trademark Office issued a notice of allowance covering tri-specific antibody constructs for the CAPTN-3 platform, a development that triggered a sharp single-day surge and elevated volume. The company also reported second-quarter 2026 results in August, detailing continued preclinical progress for IM1240.
Analyst coverage has remained a factor as well, with H.C. Wainwright maintaining a Buy rating while adjusting its price target over the period. After the September patent-driven spike, profit-taking and a general pullback in speculative biotech names pushed shares lower through October, setting the stage for the November recovery. The quarterly narrative centers on steady preclinical execution for CAPTN-3 against a backdrop of limited cash and the need to advance IM1240 toward the clinic.
PPBT Stock Forecast Drivers: What Investors Should Watch Next
Investors monitoring PPBT should focus on upcoming data and financing milestones. The oral presentation of IM1240 preclinical data at the EORTC-NCI-AACR Symposium represents the nearest meaningful catalyst. Beyond that, progress toward an investigational new drug (IND) filing and the planned clinical entry of IM1240 will be central to the company's valuation narrative.
Financing remains a key risk. With a limited cash balance and a runway measured in months-to-quarters, Purple Biotech may need additional capital through equity raises, partnerships, or other arrangements, which could dilute existing shareholders. Regulatory developments, competitive activity in multi-specific antibody programs, and broader risk appetite for speculative biotech names are additional factors that could influence the stock. As with all clinical-stage companies, investors should weigh the binary nature of drug development against their own risk tolerance.
Exploring Tickeron AI Tools for Biotech Analysis
In my view, Tickeron’s AI Trading Bots have been a practical addition to my workflow when tracking volatile names like this one. The platform lets users review a range of algorithmic strategies, from short-term swing approaches to longer-term trend models, and quickly spot which ones are showing current relevance. I’ve used the tools to cross-check sentiment signals and liquidity patterns without having to build everything from scratch. It keeps the focus on data rather than guesswork, which is especially useful in a catalyst-driven sector where timing can shift quickly.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PPBT's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for PPBT turned positive on October 30, 2026. Looking at past instances where PPBT's MACD turned positive, the stock continued to rise in 37 of 44 cases over the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on PPBT as a result. In 64 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
PPBT moved above its 50-day moving average on November 11, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +8.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where PPBT advanced for three days, in 169 of 224 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PPBT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
PPBT broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PPBT entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.172) is normal, around the industry mean (3.498). P/E Ratio (-0.027) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. PPBT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PPBT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of pharmaceutical drug discovery and development services
Industry Biotechnology
Advertisement